Key Takeaway: Eledon presented updated results from the Phase 2 BESTOW extension study at the International Congress of The Transplantation Society. Patients treated with tegoprubart demonstrated a significant improvement in kidney function, with a mean eGFR of 71 mL/min/1.73 m² compared to 58 mL/min/1.73 m² for those on tacrolimus. Importantly, there were no rejections in the tegoprubart group beyond six months.
Market Sentiment Analysis
POSITIVE FACTORS
Tegoprubart shows significant improvement in kidney function.
Patients maintained higher eGFR compared to tacrolimus.
No rejections occurred in the tegoprubart treatment group.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+92%
120-day peak, hindsight
Typical move
8.6%
average across 8 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
Tegoprubart
Phase 2 · Kidney Transplant Rejection
Full Press Release Details
Tegoprubart-treated patients maintained statistically significantly higher kidney function as measured by mean eGFR through 24 months, with an approximately 13 mL/min/1.73 m² advantage versus tacrolimus (71 vs. 58 mL/min/1.73 m²) at month 24 No rejections occurred in the tegoprubart arm beyond six
Frequently Asked Questions
What were the results of the BESTOW study?
The BESTOW study showed that tegoprubart-treated patients had significantly higher kidney function.
How did tegoprubart compare to tacrolimus?
Tegoprubart had a mean eGFR of 71 mL/min/1.73 m², outperforming tacrolimus at 58 mL/min/1.73 m².
Were there any rejections in the tegoprubart group?
No rejections occurred in the tegoprubart arm beyond six months.
Where were the study results presented?
The results were presented at the International Congress of The Transplantation Society.